Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/107210
DC FieldValueLanguage
dc.contributor.authorVieira, Raquel-
dc.contributor.authorSouto, Selma B.-
dc.contributor.authorSánchez-López, Elena-
dc.contributor.authorMachado, Ana López-
dc.contributor.authorSeverino, Patrícia-
dc.contributor.authorJose, Sajan-
dc.contributor.authorSantini, Antonello-
dc.contributor.authorFortuna, A.-
dc.contributor.authorGarcía, Maria Luisa-
dc.contributor.authorSilva, Amelia M.-
dc.contributor.authorSouto, Eliana B.-
dc.date.accessioned2023-06-15T08:05:36Z-
dc.date.available2023-06-15T08:05:36Z-
dc.date.issued2019-10-10-
dc.identifier.issn1424-8247pt
dc.identifier.urihttps://hdl.handle.net/10316/107210-
dc.description.abstractDiabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.pt
dc.language.isoengpt
dc.publisherMDPIpt
dc.relationM-ERA-NET/0004/2015-PAIRED and UID/AGR/04033/2019 (CITAB),pt
dc.relationInstitute of Nanoscience and Nanotechnology under the project ART(2018)pt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subjectdiabetes mellituspt
dc.subjectmetabolic syndromept
dc.subjectglucose-lowering agentspt
dc.subjectsugar-lowering oilspt
dc.subjectphytotherapypt
dc.titleSugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-Ipt
dc.typearticle-
degois.publication.firstPage152pt
degois.publication.issue4pt
degois.publication.titlePharmaceuticalspt
dc.peerreviewedyespt
dc.identifier.doi10.3390/ph12040152pt
degois.publication.volume12pt
dc.date.embargo2019-10-10*
uc.date.periodoEmbargo0pt
item.grantfulltextopen-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairetypearticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextCom Texto completo-
crisitem.author.orcid0000-0001-5652-9219-
crisitem.author.orcid0000-0003-2571-108X-
crisitem.author.orcid0000-0001-6527-6612-
crisitem.author.orcid0000-0002-9737-6017-
Appears in Collections:I&D CIBIT - Artigos em Revistas Internacionais
FFUC- Artigos em Revistas Internacionais
Show simple item record

SCOPUSTM   
Citations

93
checked on May 6, 2024

WEB OF SCIENCETM
Citations

82
checked on May 2, 2024

Page view(s)

63
checked on May 7, 2024

Download(s)

37
checked on May 7, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons